Satellos Bioscience Inc. MSLE
6.47 USD +0.10 (+1.57%)
At closeNov 4, 2026, 4:00 PM EST
6.47 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
6.39 Day range 6.65
5.30 52-week range 13.40
- YTD
- +10.03%
- 1 year
- +10.22%
- Market cap
- 137.27M
- EPS (ttm)
- -1.95
- YTD return
- +10.03%
- 1-year return
- +10.22%
- Volume
- 11.71K
- Avg volume
- 40.87K
- Open
- 6.55
- Previous close
- 6.37
- Day's range
- 6.39 – 6.65
- 52-week range
- 5.30 – 13.40
2Y -0.98 (-13.26%)
Financials — quick view
MSLE Revenue — quarterly 0
MSLE Net income — quarterly -11.72M
MSLE EPS — quarterly -0.56
News
Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24 
Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform 
Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age 
Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Wall Street Brokerages 
FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy - HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target
- Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate
HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $18 
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence 
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Your note
Sign in to keep a note on MSLE — it syncs with the Stock Master app.